Pneumococcus

Vaccine saves thousands from illness

Published in Biotech Business Week, May 19th, 2003

A vaccine that had its start in basic research 2 decades ago at the University of Rochester Medical Center has shown remarkable success, causing rates of infection by a persistent microbe to plummet by 69% nationwide in the span of just 3 years.

The success of the Prevnar vaccine, produced by Wyeth after the company licensed basic technology from the university, is covered in the May 1, 2003, issue of the New England Journal of Medicine. The numbers translate to roughly 20,000 fewer cases of infection each year in the United States, with the greatest prevention among the youngest children.

Prevnar was introduced in 2000 to prevent invasive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2003-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry